INTRODUCTION
============

Gastric cancer is one of the most common types of cancer worldwide^[@b1-kjim-17-4-227-3])^. Despite some improvement in its treatment, the 5-year survival rate of gastric cancer is still low. The prevalence of intestinal metaplasia (IM) is closely related to *H. pylori* infection^[@b2-kjim-17-4-227-3])^. Furthermore, chronic gastritis due to *H. pylori* infection may progress to IM and even gastric cancer^[@b3-kjim-17-4-227-3]--[@b5-kjim-17-4-227-3])^. *H. pylori*-induced inflammation facilitates gastric carcinogenesis by increasing the rate of cell replication, decreasing the concentration of ascorbic acid and inducing DNA damage via reactive oxygen species^[@b6-kjim-17-4-227-3],\ [@b7-kjim-17-4-227-3]^. Both environmental and genetic factors are crucial in the multistage model of gastric tumorigenesis^[@b3-kjim-17-4-227-3])^. A preliminary observation has suggested that both IM and *H. pylori* infection are important targets in the prevention of gastric cancer^[@b8-kjim-17-4-227-3])^.

Telomerase, located at the distal end of human chromosomes, comprises simple, repetitive and G-rich hexameric sequences (TTAGGG), and is vital for chromosomal stability and replication. Telomerase is a ribonucleoprotein polymerase that adds telomeric sequences onto the ends of the chromosome to compensate for the DNA end-replication problem. Thus, this activity is strongly associated with cell immortalization and carcinogenesis, and its presence is elevated in 85% of human cancers, including those associated with the stomach, colon, breast, bladder, prostate, liver, lung and ovary. The measurement of telomerase activity may become a diagnostic tool for cancer^[@b9-kjim-17-4-227-3])^. However, telomerase activity can also be found in precancerous lesions, such as IM^[@b10-kjim-17-4-227-3])^.

In this study, we evaluated the relationships of both *H. pylori* infection and telomerase activity with endoscopic and histologic features in IM. The effects of *H. pylori* eradication on endoscopic, histologic and biochemical changes were evaluated.

PATIENTS AND METHODS
====================

This study involved 43 patients who, between January 1999 and June 2000, were diagnosed with IM without any gastroenterologic diseases by an upper gastrointestinal endoscopic examination at a gastrointestinal endoscopy unit of Soonchunhyang University Chonan hospital. Thirty-four of these patients were diagnosed as having *H. pylori* infection. Eight patients exhibited elevated telomerase activity. Twenty-three of the patients with *H. pylori* infection were treated with an *H. pylori* eradication regimen and fifteen of them were able to be followed up for changes in endoscopic, pathologic and telomerase results after 4 months of complete therapy.

1). Gastric tissue sampling by upper gastrointestinal endoscopy
---------------------------------------------------------------

Six gastric specimens were obtained by endoscopic biopsy of the IM lesion. Two of these specimens were fixed in 10% buffered formalin, embedded in paraffin and sectioned, and then one was stained with hematoxylineosin (H & E) and/or WarthinStarry silver stain for detecting *H. pylori*. The other specimens were stained using the high-iron diamine (HID)/alcian blue (AB) technique to differentiate acidic mucin into sialomucins (blue) and sulfomucins (brown-black)^[@b11-kjim-17-4-227-3])^. The other two specimens were used to detect telomerase activity. One set of gastric tissue from the antrum and body was obtained and used for the Campylobacter Like Organism (CLO) test and monitored for color changes for up to 24 h at room temperature.

2). Grading of intestinal metaplasia
------------------------------------

Endoscopic grades were classified according to the degree and pattern of mucosal elevation: I, granular; II, nodular; III, irregular or confluent. The extent of IM, as assessed endoscopically, was graded as follows: I, confined to antrum; II, extending to lower body; III, extending to upper body and fundus. Histologic grading is classified by HID/AB and H&E staining. Metaplastic lesions were classified into three subtypes: type I, complete IM characterized as resembling the normal intestinal epithelium; type II, incomplete IM expressing sialomucins but not sulfomucin; and type III, incomplete IM expressing sulfomucins. If IM of more than one subtype was present in a given sample, the case was assigned to the least mature subtype, as proposed previously^[@b2-kjim-17-4-227-3])^.

3). Telomerase assay
--------------------

Protein extracts were obtained and a telomerase activity assay was performed as described previously^[@b12-kjim-17-4-227-3])^. One to three milliliters of tissue extract (1--50 *μ*g of total protein) was subjected to a modified, semiquantitative telomeric repeat amplification protocol, which included an internal telomerase assay standard^[@b13-kjim-17-4-227-3])^. A polymerase chain reaction (PCR) was performed using a thermal cycler (DNA engine: Peltier thermal cycler, MJ Research, Waltham, Mass., USA) using primer elongation at 25°C for 10 min and inactivation at 94°C for 5 min. Thirty-three PCR cycles were performed which consisted of 94°C for 30 s, 50°C for 30 s and 72°C for 90 s. After hybridization using digoxin and a telomeric repeat sequence, the absorbancy was measured at 450 nm by a microtiter plate (ELISA) reader. Negative and positive controls were read using a PCR ELISA kit (TeloTAGGG Telomerase PCR ELISA^PLUS^, Roche, Nutley, N.J., USA). The final value was obtained by subtraction of the mean of the absorbance readings of the negative controls from the absorbance readings of the samples (i.e., AsAs.o). Samples are considered as telomerase-positive if the difference in absorbance (A) is higher than two times the background activity. Quantification of telomerase activity was determined as the relative telomerase activity using a formula provided in the PCR ELISA kit.

4). *H. pylori* eradication and follow-up
-----------------------------------------

The *H. pylori* eradication regimen was administrated to 15 patients with *H. pylori* infection for 2 weeks as 20 mg omeprazole, 1000 mg amoxicillin and clarithromycin 500 mg twice per day. Four months later we performed endoscopic, histologic, and biochemical evaluations.

5). Statistical analysis
------------------------

Statistical analysis was performed using the Stata program (Release 5.0; Stata, College Station, Texas, USA). The chi-square or Fishers exact test was utilized to analyze differences in the proportions of *H. pylori* infection status or telomerase activity in the endoscopic and histologic findings. The Wilcoxon signed rank test was utilized when comparing paired samples, *p* values less than 0.05 were considered to be statistically significant.

RESULTS
=======

1). General profiles
--------------------

The mean (SD) age of the subjects was 52.2 (11.1) years and 29 (67.4%) of them were male. The nodular pattern and grade-III extent was prevalent (24, 55.8%; 20, 46.5%; respectively) in the endoscopic findings. The prevalence of subtype II (21, 44.8%) and mild grade (18, 41.9%) was highest in histologic findings. Thirty-four (79.1%) patients showed *H. pylori* infection and eight (18.6%) had elevated telomerase activity ([Table 1](#t1-kjim-17-4-227-3){ref-type="table"}).

2). Clinical features and *H.pylori* infection
----------------------------------------------

The granular type was significantly higher in *H. pylori* infection (11, 32.4% vs 0, 0%, *p*=0.03) and the increase in grade-I extent was borderline significant (9, 26.5% vs 0, 0% *p=*0.076) in endoscopic findings. However, *H. pylori* infection rates were not significantly different according to histologic subtype (*p*=0.473) or severity (*p*=0.704) ([Table 2](#t2-kjim-17-4-227-3){ref-type="table"}).

3). Clinical features and telomerase activity
---------------------------------------------

Telomerase activity was detected in eight (18.6%) patients. Telomerase activity showed a high tendency in subtype III of IM, but without statistical significance (*p*=0.179). There was no relation between histologic severity of IM and telomerase activity (*p*=0.731). There were no significant relationships between endoscopic pattern and telomerase activity, but telomerase activity showed a high tendency in a wide extent of IM ([Table 3](#t3-kjim-17-4-227-3){ref-type="table"}).

4). Follow-up after *H. pylori* eradication
-------------------------------------------

We performed repeat endoscopic and histologic examinations and evaluated telomerase activity in 15 patients to compare the quantitative changes in the activities (relative telomerase activity). Eight and ten out of 15 patients were downgraded or improved according to histologic subtype (*p*=0.671) and severity (*p*=0.074), respectively. In endoscopy, five and six patients showed improvement of pattern (*p*=0.151) and extent (*p*=0.039), respectively. There was a significant difference in extent grading between initial and follow-up after *H. pylori* eradication according to endoscopic findings (*p*=0.039) ([Table 4](#t4-kjim-17-4-227-3){ref-type="table"}). Telomerase activity showed a significant decrease in this period (1321.5±870.8 vs 373.2±560.68, *p*=0.0001) ([Figure 1](#f1-kjim-17-4-227-3){ref-type="fig"}).

DISCUSSION
==========

Telomerase activity in humans has been detected in germ lines and tumor tissues as well as in established cultured-cell lines^[@b14-kjim-17-4-227-3])^. In normal somatic cells, the absence or low expression of telomerase is thought to result in progressive telomeric shortening with each cell division. Therefore, it has been proposed that reactivation of telomerase is a critical step in tumorigenesis. The expression of telomerase may occur at different stages of cancer progression, depending on the type of malignancy^[@b15-kjim-17-4-227-3]--[@b19-kjim-17-4-227-3])^.

Telomerase activity has been detected in approximately 35% of noncancerous lesions, such as gastric IM,^[@b10-kjim-17-4-227-3])^ although the level is generally lower than in cancerous tissue. In addition, genetic alterations, such as p53^[@b20-kjim-17-4-227-3])^ and APC gene mutations^[@b21-kjim-17-4-227-3])^, are found in IM and gastric cancer. These genetic changes and the activation of telomerase in IM and so-called precancerous lesions may contribute to the carcinogenic process in intestinal gastric cancers^[@b20-kjim-17-4-227-3])^. Furthermore, detection of telomerase activity in both cancer and IM suggests that telomerase activation is an early event in stomach carcinogenesis. In our study, telomerase activity was detected in 18.6% of patients.

IM is the common endoscopic feature that occurs at an average age of 14 years after superficial and/or atrophic gastritis. The occurrence of chronic atrophic gastritis has a complex relationship to *H. pylori* infection, genetics, diet, drugs, smoking, alcohol, high salt intake, vitamin-C deficiency and environmental factors. IM is the replacement of gastric mucosal cells with intestinal cells (including goblet cells). Regression of IM after *H. pylori* eradication is debatable in many histologic studies^[@b22-kjim-17-4-227-3]--[@b31-kjim-17-4-227-3])^, and studies on endoscopic changes are also limited.

We randomly classified the endoscopic grade and extent of IM according to the nature of gross severity. Through the classification, we assessed the relationship between endoscopic features and *H. pylori* infection or telomerase activities and we evaluated the significance of these endoscopic findings on the basis of histology and molecular biology. We also observed the changes of these endoscopic classifications and histologic and molecular biologic changes as detailed markers of precancerous lesions after *H. pylori* eradication. In our study, changes in the grade of the pattern of IM were not statistically significant and the extent of IM tended to decrease. These changes represent the possibility of regression of endoscopic findings. The *H. pylori* infection rate was high in the endoscopic granular type which was suspected as being a relatively low-grade lesion. The *H. pylori* infection rate had a tendency to be higher in the grade-I extent of IM than grade-II or III extent. These results suggest indirectly that the *H. pylori* infection rate is high in the early stages of IM, and suggest that *H. pylori* cannot survive for long enough to allow migration from the antrum to the upper body by the progression of IM. Among the eight patients with telomerase activity, there was no significant relationship between the endoscopic pattern of IM and telomerase activity, but telomerase activity tended to be detected in grade-III extent. These findings suggest that the endoscopic extent of IM represents the duration of *H. pylori* infection and premalignant tendency of IM.

The relationships between the histologic characteristics of IM and *H. pylori* infection have been studied extensively. In the present study, the *H. pylori* infection rate did not differ significantly with histologic subtype and severity. Telomerase activity tends to be high in subtype III of IM; this subtype is known to be more precancerous in nature than other histologic types in pathologic studies.^[@b32-kjim-17-4-227-3])^ The number of subjects in our study is too small to allow us to say definitively that subtype III of IM has a precancerous nature at the molecular level. There was no relation between the histologic severity of IM and telomerase activity. The nature of the precancerous lesion did not depend on histologic severity, but subtype is more important in the prediction of cancerous changes in IM. The histologic subtype was changed in 73.3% of cases with IM and the severity of IM tended to decrease. Metaplastic changes disappeared in 20% of cases. Taken together, these observations suggest the possibility of reversibility of IM after *H. pylori* eradication.

Our study suffered from some limitations associated with the use of endoscopic biopsies, but these are unavoidable in a clinical study. However, we used special staining techniques to maximize our ability to assess the pattern and extent of IM, and we recorded the lesion site to allow re-examining of the same site by endoscopic biopsy. Another problem is that a relatively small number of subjects was included in this study to induce a statistically significant result for comparing the relationship among various factors, which needs subsequent more studies to confirm the clinical significance of relating factors in patients with IM.

The changes in quantitation of telomerase activities (relative telomerase activity) was significantly decreased in patients regardless of the positivity of the telomerase activity. These results suggest that *H. pylori* eradication is needed in *H. pylori*-infected patients with IM, especially those that have endoscopic findings of widespread and histologic subtype III IM.

To conclude, in IM a widespread endoscopic lesion and histologic subtype III produces a tendency for high telomerase activity, which is a predictable marker of malignant changes. *H. pylori* eradication improved the endoscopic and histologic features and decreased telomerase activity. We carefully suggest that *H. pylori* eradication can be considered one of the methods to prevent gastric cancer in patients with *H. pylori* infected IM. Further long-term and large scaled study will be needed.

Some of the results in this paper were presented at Digestive Disease Week (DDW), Atlanta, May 2001.

![The endoscopic pattern of IM. Granular is defined as type I (A), nodular as type II (B) and confluent as type III (C).](kjim-17-4-227-3f1){#f1-kjim-17-4-227-3}

![The endoscopic extent of IM. IM in antrum is defined as grade I (A), extending to lower body as grade II (B) and extending to upper body and fundus as grade III (C).](kjim-17-4-227-3f2){#f2-kjim-17-4-227-3}

![The histologic subtype of IM. Type I is incomplete IM characterized as resembling the normal intestinal epithelium (A), type II is complete IM expressing sialomucins but not sulfomucins (B) and type III is incomplete IM expressing sulfomucins (C).](kjim-17-4-227-3f3){#f3-kjim-17-4-227-3}

![Box plots comparing telomerase activity between initial and follow-up conditions in 15 patients after *H. pylori* eradication](kjim-17-4-227-3f4){#f4-kjim-17-4-227-3}

###### 

General profiles of study subjects (*H. pylori, Helicobacter pylori)*

  Characteristic           Classification          N (%)
  ------------------------ ----------------------- -------------
  Age in years: mean(SD)                           52.2 (11.1)
  Sex                      Male                    29 (67.4)
  Female                   14 (32.6)               
  Histology                Subtype                 
    I                      17 (39.5)               
    II                     21 (44.8)               
    III                    5 (11.6)                
  Severity grade                                   
    Mild                   18 (41.9)               
    Moderate               9 (20.9)                
    Severe                 16 (37.2)               
  Endoscopy                Pattern                 
    Granular               11 (25.6)               
    Nodular                24 (55.8)               
    Confluent              8 (18.6)                
  Degree of extent                                 
    I                      9 (20.9)                
    II                     14 (32.6)               
    III                    20 (46.5)               
  Chemistry                *H. pylori* infection   
    Yes                    34 (79.1)               
    No                     9 (20.9)                
  Telomerase               Activity                
    Positive               8 (18.6)                
    Negative               35 (81.4)               
                                                   
                           Total                   43 (100)

###### 

Clinical features of intestinal metaplasia (IM) according to *H. pylori* infection

  Clinical           Classification   *H. pylori* positive (N=34)   *H. pylori* negative (N=9)   *p* value
  ------------------ ---------------- ----------------------------- ---------------------------- -----------
  Histology          Subtype                                                                     0.473
    I                13 (30.2)        4 (44.4)                                                   
    II               16 (47.1)        5 (55.6)                                                   
    III              5 (14.7)         0 (0)                                                      
  Severity grade                                                    0.704                        
    Mild             14 (41.2)        4 (44.4)                                                   
    Moderate         8 (23.5)         1 (11.1)                                                   
    Severe           12 (35.3)        4 (44.4)                                                   
                                                                                                 
  Endoscopy          Pattern                                                                     0.03
    Granular         11 (32.4)        0 (0)                                                      
    Nodular          19 (55.9)        5 (55.6)                                                   
    Confluent        4 (11.7)         4 (44.4)                                                   
  Degree of extent                                                  0.076                        
    I                9 (26.5)         0 (0)                                                      
    II               12 (35.3)        2 (22.2)                                                   
    III              13 (38.2)        7 (77.8)                                                   

###### 

Clinical features of IM according to telomerase activity

  Clinical           Classification   Telomerase positive (N=8)   Telomerase negative (N=35)   *p* value
  ------------------ ---------------- --------------------------- ---------------------------- -----------
  Histology          Subtype                                                                   0.179
    I                2                14                                                       
    II               4                17                                                       
    III              2                3                                                        
  Severity grade                                                  0.731                        
    Mild             4                14                                                       
    Moderate         2                7                                                        
    Severe           2                3                                                        
                                                                                               
  Endoscopy          Pattern                                                                   0.871
    Granular         2                9                                                        
    Nodular          4                20                                                       
    Confluent        2                6                                                        
  Degree of extent                                                0.159                        
    I                1                8                                                        
    II               2                12                                                       
    III              5                15                                                       

###### 

Comparisons between initial and follow-up conditions after *H. pylori* eradication in 15 patients with IM

  Clinical      Classification   Change        N       *p* value[^\*^](#tfn1-kjim-17-4-227-3){ref-type="table-fn"}
  ------------- ---------------- ------------- ------- -------------------------------------------------------------
  Histology     Subtype          Downgraded    8       0.671
  Same          4                                      
  Upgraded      3                                      
  Severity      Improvement      10            0.074   
  Same          1                                      
  Aggravation   4                                      
  Endoscopy     Pattern          Improvement   5       0.151
  Same          9                                      
  Aggravation   1                                      
  Extent        Improvement      6             0.039   
  Same          8                                      
  Aggravation   1                                      

by Fishers exact test
